

**Table 1.** *Trials of agents demonstrating favorable results in the treatment of patients with SLE.*

Regimen	Phase of the study / Indication	Primary endpoint	Result
Obinutuzumab	II / lupus nephritis	Complete renal response at week 52	35% (Obinutuzumab) vs 23% (placebo), p=0.115
Obexelimab	II / SLE	Loss of improvement at day 225	42% (obexelimab) vs 28.6% (placebo), p=0,18
Lupuzor	III / SLE	SRI response at week 52	52.5% (lupuzor) vs 44.65% (placebo), p=0.26
Daratumumab	Case report / SLE and lupus nephritis		
Belimumab	FDA approved / lupus nephritis	Primary efficacy renal response at week 104	43% (belimumab) vs 32% (placebo), p=0.03
Telitacicept	2b / SLE	SRI-4 response at week 48	71.0% (80mg), 68.3% (160mg), 75.8% (240mg) vs 33.9% (placebo), p<0.001, p<0.001, p<0.001, respectively
Anifrolumab	FDA approved / SLE	BICLA response at week 52	47.8% (anifrolumab) vs 31.5% (placebo), p=0.001
Voclosporin	FDA approved / lupus nephritis	Complete renal response at week 52	40.8% (voclosporin) vs 22.5% (placebo), p<0.0001
Sirolimus		1/2 / SLE	Decreases of BILAG and SLEDAI scores at each visit (months 1-12) BILAG: 28.4 (baseline) vs 17.4 (month 12), p<0.001 SLEDAI: 10.2 (baseline) vs 4.8 (month 12), p<0.001
		Retrospective / lupus nephritis	Proteinuria: 2.8±1.9 at baseline vs 0.1±0.1 at month 36
VIB7734		I / SLE, Sjogren's and CLE	Median change in CLASI-A from baseline to month 3: -5 (50mg), -9.5 (150mg), -5 (placebo)
BIIB059		II / SLE (part A)	Change of total joint count from baseline to week 24 CLASI-A at week 16 -15.0 (450mg) vs -11,6 (placebo), p=0.037
		CLE (part B)	-38.78 (50mg), -47.91 (150mg), -42.48 (450mg) vs -14.49 (placebo), p=0.015, p<0.001, p=0.001